Idexx Laboratories Inc
IDXXIdexx Laboratories Inc is a global provider of veterinary diagnostics, software, and services for animal health. The company develops testing solutions to help veterinarians diagnose and monitor health conditions in animals, including in-clinic diagnostic instruments, laboratory diagnostic services, and veterinarian practice management software. Founded in 1983, Idexx has established itself as a leading innovator in veterinary medical diagnostics and animal health solutions.
Company News
The global livestock monitoring market is projected to grow from $6.2 billion in 2025 to $10.3 billion by 2030 at a 10.6% CAGR, driven by AI-enabled precision farming, IoT sensors, and wearable technologies. Europe leads with 33.2% market share, while regulatory compliance and rising protein demand are key growth catalysts.
The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America le...
IDEXX Laboratories reported strong Q1 2026 results with EPS of $3.47 (beating consensus of $3.41) and sales of $1.14 billion (above consensus of $1.109 billion), driven by higher clinical visits and diagnostic frequency. The company raised its full-year 2026 guidance for both earnings ($14.45-$14.90 vs. previous $14.29-$14.80) and sales ($4.675-$...
The global veterinary reference laboratory market is projected to grow from USD 6.12 billion in 2025 to USD 13.93 billion by 2035, driven by rising pet ownership, pet humanization trends, and increased demand for advanced diagnostics. However, high infrastructure costs and shortage of skilled specialists pose challenges to market expansion.
IDEXX Laboratories reported better-than-expected Q4 2025 earnings of $3.08 per share (beating $2.94 consensus) with $1.091 billion in sales (beating $1.073 billion consensus) and strong growth across segments. The company issued 2026 guidance of $14.29-$14.80 EPS and $4.632-$4.720 billion in sales. Despite the positive results and strong innovati...
